Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.

Recent News

September 10, 2018
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference

August 27, 2018
Editas Medicine Announces Transition of Chief Medical Officer

August 16, 2018
Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process

Read More News

Associated Team Members

Alexis Borisy